Intellia Therapeutics
Trending Articles
Related Content
Manufacturing
Collaboration is key to advancing cell and gene therapy
The potential for cell and gene therapies to address a wide range of diseases is reflected in the sheer size of the pipeline. As of the start of this year, more than 2000 gene and modified cell therapies, such as chimeric antigen receptor T-cell (CAR-T) treatments, were under development, along with 800-plus non-genetically modified cell therapies(1)